Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

JA Johnson; KE Caudle; L Gong; M Whirl‐Carrillo; CM Stein; SA Scott; MT Lee; BF Gage; SE Kimmel; MA Perera; JL Anderson; M Pirmohamed; TE Klein; NA Limdi; LH Cavallari; M Wadelius

doi:10.1002/cpt.668

journal article Apr 04, 2017

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

JA Johnson KE Caudle L Gong M Whirl‐Carrillo CM Stein SA Scott MT Lee BF Gage SE Kimmel MA Perera JL Anderson M Pirmohamed TE Klein NA Limdi LH Cavallari M Wadelius

Clinical Pharmacology & Therapeutics Vol. 102 No. 3 pp. 397-404 · Wiley

View at Publisher Save 10.1002/cpt.668

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype‐guided warfarin dosing to achieve a target international normalized ratio of 2–3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

10.1038/clpt.2010.279

[2]

10.1007/s11239-006-5580-y

[3]

Pharmacology and Management of the Vitamin K Antagonists

Jack Ansell, Jack Hirsh, Elaine Hylek et al.

Chest 10.1378/chest.08-0670

[4]

Antithrombotic Therapy for VTE Disease

Clive Kearon, Elie A. Akl, Joseph Ornelas et al.

Chest 10.1016/j.chest.2015.11.026

[5]

10.1001/archinternmed.2010.407

[6]

10.1038/nature02214

[7]

10.1016/s0140-6736(13)60681-9

[8]

10.1097/00008571-200204000-00010

[9]

Gene Reference Materials for CYP2C9. <https://www.pharmgkb.org/page/cyp2c9RefMaterials> (2016). Accessed 4 November 2016.

[10]

10.1182/blood-2009-12-255992

[11]

10.1016/s0140-6736(98)04474-2

[12]

10.1016/s0140-6736(14)61994-2

[13]

10.1074/jbc.m505373200

[14]

10.1038/sj.tpj.6500313

[15]

10.1093/hmg/ddi180

[16]

10.1038/clpt.2008.10

[17]

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

New England Journal of Medicine 10.1056/nejmoa0809329

[18]

10.1056/nejmoa044503

[19]

Gene Reference Materials for VKORC1. <https://www.pharmgkb.org/page/vkorc1RefMaterials>. Accessed 4 November 2016.

[20]

10.1016/j.ajhg.2007.10.002

[21]

10.1124/mol.109.054833

[22]

10.1182/blood-2007-11-122010

[23]

10.1152/physiolgenomics.00003.2007

[24]

Gene Reference Materials for CYP4F2. <https://www.pharmgkb.org/page/cyp4f2RefMaterials>. Accessed 4 November 2016.

[25]

10.2217/14622416.10.2.261

[26]

10.1038/clpt.2012.184

[27]

10.1097/fpc.0b013e3283311347

[28]

10.1097/fjc.0000000000000317

[29]

10.1055/s-0037-1614152

[30]

10.1182/blood-2008-04-149070

[31]

10.1016/j.thromres.2011.11.043

[32]

10.1056/nejmoa1310669

[33]

10.1056/nejmoa1311386

[34]

10.1097/fpc.0000000000000108

[35]

10.1038/tpj.2011.18

[36]

10.1038/clpt.2010.13

[37]

10.1038/clpt.2011.186

[38]

10.1016/j.jacc.2010.08.643

[39]

Arwood M.J. "Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real‐world setting: A proposal for a new pharmacogenetic dosing approach" Clin. Pharmacol. Ther.

[40]

10.1007/s00228-012-1466-4

[41]

10.1182/blood-2011-08-372722

[42]

10.1111/bcp.12308

[43]

10.1038/clpt.2010.37

[44]

10.1136/bmj.325.7372.1073

[45]

10.7326/0003-4819-150-2-200901200-00005

[46]

10.1111/j.1538-7836.2009.03677.x

Cited By

611

The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay

Si Cheng, Zhe Xu · 2023

Cell Discovery

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms

Rhonda M. Cooper‐DeHoff, Mikko Niemi · 2022

Clinical Pharmacology & Therape...

Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates

Zeina N. Al-Mahayri, Lubna Q. Khasawneh · 2022

Human Genomics

Metrics

611

Citations

46

References

Details

Published: Apr 04, 2017
Vol/Issue: 102(3)
Pages: 397-404
License: View

Authors

J

JA Johnson

Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics University of Florida Gainesville Florida USA

K

KE Caudle

Department of Pharmaceutical Sciences St. Jude Children's Research Hospital Memphis Tennessee USA

L

L Gong

Department of Biomedical Data Science Stanford University Stanford California USA

M

M Whirl‐Carrillo

Department of Biomedical Data Science Stanford University Stanford California USA

C

CM Stein

Division of Clinical Pharmacology Vanderbilt Medical School Nashville Tennessee USA

S

SA Scott

Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA

M

MT Lee

Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; National Center for Genome Medicine; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Genomic Medicine Institute Geisinger Health system Danville Pennsylvania USA

B

BF Gage

Department of Internal Medicine Washington University in St. Louis St. Louis Missouri USA

S

SE Kimmel

Center for Clinical Epidemiology and Biostatistics University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA; Department of Medicine and Department of Biostatistics and Epidemiology University of Pennsylvania School of Medicine Philadelphia Pennsylvania USA

M

MA Perera

Department of Medicine University of Chicago Chicago Illinois USA

J

JL Anderson

Intermountain Heart Institute, Intermountain Medical Center, and Department of Internal Medicine (Cardiology) University of Utah School of Medicine Salt Lake City Utah USA

M

M Pirmohamed

Department of Molecular and Clinical Pharmacology; The Wolfson Centre for Personalised Medicine; Institute of Translational Medicine University of Liverpool Liverpool UK

T

TE Klein

Department of Biomedical Data Science Stanford University Stanford California USA

N

NA Limdi

Department of Neurology and Epidemiology University of Alabama at Birmingham Birmingham Alabama USA

L

LH Cavallari

Department of Pharmacotherapy and Translational Research, College of Pharmacy, and Center for Pharmacogenomics University of Florida Gainesville Florida USA

M

M Wadelius

Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory Uppsala University Uppsala Sweden

Funding

National Institutes of Health Award: R24GM115264

Swedish Research council Award: Medicine 521‐2011‐2440

Cite This Article

JA Johnson, KE Caudle, L Gong, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology & Therapeutics, 102(3), 397-404. https://doi.org/10.1002/cpt.668

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

You May Also Like